Contents Editor’s Letter Medical journal publication during global stress Editorial Is the local tolerance of injectable biosimilars too underestimated? Commentary A white paper: US biosimilars market on pace with Europe Original Research Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags Local policies on biosimilars: are they designed to…

Author(s): Michael Cohan

Innovator drug sourcing challenges

Contents Editor's Letter Latest features in GaBI Journal, 2012, issue 3-4 Letters to the Editor A bioethicist’s view of the use of biosimilars A clinician’s view of the ethics of the use of biosimilars Editorial Generics policies–a globally-relevant implementation challenge Reference price systems: stakeholder dialogue and involvement Commentary Statin generics: no differences in efficacy after…

Contents Editor’s Letter What to look forward to in GaBI Journal, 2018, Issue 2 Commentary Potential changes to the FDA approach to biosimilars have a global impact Original Research Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2 Review Article Protein heterogeneity and…

Contents Editor’s Letter Editor’s introduction to the initial issue of the eighth volume of GaBI Journal Legal Biosimilars: considerations in light of the Italian legal framework Special Report Patent expiry dates for biologicals: 2018 update Pharma News Top developments in biosimilars during 2018 Abstracted Scientific Content Regulatory requirements for the acceptance of foreign comparator products…

Author(s): Jennifer Campbell

Review Article

Published on 04 May 2026

Bridging the global health equity gap: the impact of local biological manufacturing on patient access in Iran

Introduction/Study Objectives: Biological therapies have revolutionized the treatment of cancers, autoimmune, and metabolic diseases. However, access to these life-saving treatments remains severely limited in low- and middle-income countries due to high costs and infrastructure deficits. This study evaluates the impact of local manufacturing of biosimilars and complex biologicals on patient access in Iran, a lower-middle-income…

Author(s): Soheil Roshanzamiri, PharmD, Deyhim Atarod, PhD, Elmira Sayari, PharmD

access to medicines, biopharmaceutical manufacturing, biosimilars, health gain, Iran, pharmacoeconomics

DOI: 10.5639/gabij.2026.1502.

Contents Editor's Letter Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal Letters to the Editor The ethics of biosimilars Austria increases dialogue in order to involve physicians more with biosimilars Editorial Health authority perspective on biosimilars Commentary The case for biosimilars–a payer’s perspective Original…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2017. Professor Daan JA Crommelin, The Netherlands Dr Alessandro Curto, Italy Professor Francisco Jose de Abajo Iglesias, Spain Professor Theodor Dingermann, Germany…

Contents Editor’s Letter What to look forward to in GaBI Journal, 2021, Issue 2 Original Research Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching Variation in the prices of oncology medicines across Europe and the implications for the future Review…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2012. Ms Arpah Abas, Malaysia Dr Ibrahim Alshwaier, Saudi Arabia Professor Saleh Alsuwayeh, Saudi Arabia Dr Christoph Baumgärtel, Austria Professor Daniel Benjamin, USA…

Special Report

Published on 18 May 2026

Economic feasibility of ‘Pay One Price’: an analysis of three biosimilar molecules with different prices and indicated for rheumatoid arthritis in a medium size HMO 

Introduction/Objective: To evaluate the economic feasibility of a uniform ‘Pay One Price’ (POP) pricing model for three tumour necrosis factor (TNF) inhibitor biosimilars (adalimumab, infliximab, etanercept) used in rheumatoid arthritis (RA) treatment within a Brazilian medium-sized health maintenance organization (HMO). Methods: Medication prices were obtained from Brazil’s Chamber for the Regulation of the Medicines Market (CMED).…

Author(s): Francisco Eduardo Prota, MD, PhD, Ricardo Luiz Pereira Bueno, BA, MHA, PhD, Nanci Utida, MD

biosimilars, Brazil, budget impact analysis, Pay One Price, rheumatoid arthritis, TNF-α inhibitor

DOI: 10.5639/gabij.2026.1502.